缬沙坦胶囊联合盐酸胺碘酮治疗扩张型心肌病伴室性心律失常的效果

Abstract
Figure/Table
References (21)
Related Citation (4)

Download: PDF (373 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Valsartan Capsules combined with Amiodarone Hydrochloride in the treatment of dilated cardiomyopathy (DCM) with ventricular arrhythmia (VA). Methods Eighty DCM patients with VA admitted to Danzhou People′s Hospital from April 2017 to June 2018 were selected. The patients were divided into the control group (n = 40) and the study group (n = 40) according to the random number table method. The control group was treated with Aamiodarone Hydrochloride, and the study group was treated with Valsartan Capsules on this basis, both of which were treated continuously for 3 months. The clinical effect of the two groups after treatment, the left ventricular remodeling index [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), N terminal b-type brain natriuretic peptide (NT - proBNP)], QT dispersion degree index [QT dispersion degree (QTd), corrected QT dispersion degree (QTcd)] between two groups before and after the treatment were compared, the adverse reactions of two groups during treatment were recorded. Results The total effective rate of the study group was higher than of the control group (P ＜ 0.05). After treatment, LVEF of patients in the two groups was increased compared with that before treatment, and the study group was higher than that of the control group (P ＜ 0.05). LVEDD, LVESD and NT-proBNP were all lower than those before treatment, and the study group was lower than the control group (P ＜ 0.05). After treatment, QTd and QTcd of both groups were lower than those before treatment, and the research group was lower than the control group (P ＜ 0.05). Comparison of the total incidence of adverse reactions between the two groups showed no statistically significant difference (P ＞ 0.05). Conclusion Valsartan Capsules combined with Amiodarone Hydrochloride for the treatment of DCM patients with VA has a significant effect, which can effectively improve the left ventricular remodeling and QT dispersion in patients without increasing the incidence of adverse reactions, which has a certain clinical application value.

Key words： Valsartan Capsules Amiodarone hydrochloride Dilated cardiomyopathy Ventricular arrhythmia

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAI Jinping1 CHEN Qinghua2 LIN Mingli3 CHEN Shanshan1

Cite this article:

CAI Jinping1 CHEN Qinghua2 LIN Mingli3 CHEN Shanshan1. Effect of Valsartan Capsules combined with Amiodarone Hydrochloride in the treatment of dilated cardiomyopathy with ventricular arrhythmia[J]. 中国医药导报, 2019, 16(25): 149-152.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I25/149

[1] 梁永忠.扶阳法在扩张型心肌病中的应用[J].国际中医中药杂志，2016，38（12）：1130.
[2] 巫雪飞，黄燕，房晓楠，等.扩张型心肌病患者经标准药物治疗后左心室射血分数恢复正常的发生率及预测因素分析[J].中国循环杂志，2015，30（5）：417-421.
[3] 曾马徐.胺碘酮在急诊治疗快速型心律失常中的临床疗效及安全性探究[J].中国实用医药，2018，13（6）：105-106.
[4] 陈劲松，刘运阳，曾高峰，等.盐酸吡格列酮胶囊联合缬沙坦胶囊治疗代谢综合征的临床研究[J].中国临床药理学杂志，2017，33（18）：1748-1750，1760.
[5] 复旦大学上海医学院.《实用内科学》第13版[J].中国医刊，2009，44（12）：43.
[6] 中华医学会心血管病学分会.心肌病诊断与治疗建议[J].中华心血管病杂志，2007，35（1）：5-16.
[7] 葛晓丽.美托洛尔协同胺碘酮用于抗室性心律失常40例[J].中国药业，2015，24（19）：128-129.
[8] Zhao J，Lv T，Quan J，et al. Identification of target genes in cardiomyopathy with fibrosis and cardiac remodeling [J]. J Biomed Sci，2018，25（1）：63.
[9] 樊朝美，安硕研.2017年英国超声心动图学会扩张型心肌病诊断和评估指南解读[J].中国循环杂志，2017，32（z2）：139-144.
[10] Paldino A，De Angelis G，Merlo M，et al. Genetics of Dilated Cardiomyopathy：Clinical Implications [J]. Curr Cardiol Rep，2018，20（10）：83.
[11] 罗兴文，史海燕.盐酸胺碘酮片对老年冠心病合并心律失常患者血流动力学的影响[J].中国老年学杂志，2015， 35（14）：4042-4043.
[12] 王道敏，张春艳.盐酸胺碘酮片对老年冠心病合并心律失常患者血流动力学的影响分析[J].中国现代药物应用，2017，11（18）：92-93.
[13] Omotobara-Yabe T，Kuga S，Takeguchi M，et al. Vitamin D deficiency associated with dilated cardiomyopathy in early infancy caused by maternal cholestasis [J]. Clin Pediatr Endocrinol，2018，27（3）：187-192.
[14] 王岚.丹参多酚酸盐联合缬沙坦治疗高血压肾病45例临床评价[J].中国药业，2018，27（14）：44-46.
[15] Musko M，Sznitowska M. Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan [J]. Acta Pharm，2014，64（4）：463-474.
[16] 赵彩霞，牛彩娟，牛剑武，等.参麦注射液联合缬沙坦胶囊治疗慢性心力衰竭的效果观察[J].中西医结合心血管病电子杂志，2016，4（5）：70-71.
[17] 高艳红.盐酸胺碘酮联合复方丹参滴丸治疗冠心病并快速型心律失常临床疗效观察[J].中国实用医药，2015， 10（2）：6-8.
[18] Amin MM，El Gazayerly ON，Abd El-Gawad NA，et al. Effect of formulation variables on design，in vitro evaluation of valsartan SNEDDS and estimation of its antioxidant effect in adrenaline-induced acute myocardial infarction in rats [J]. Pharm Dev Technol，2016，21（8）：909-920.
[19] 李巍，晋学庆，王华军，等.缬沙坦对心梗大鼠心脏血管紧张素转换酶2表达的影响[J].福建医药杂志，2015， 37（6）：82-85.
[20] 马战胜.缬沙坦在扩张型心肌病中的临床应用[J].临床研究，2016，24（6）：43-43.
[21] Komeda M，Fujiwara S，Ujiie T. [Surgery for Functional Mitral Regurgitation or Dilated Cardiomyopathy in Patients with Non-transplant Candidates] [J]. Kyobu Geka，2018，71（7）：488-493.